Researchers at George Washington University hope to develop a vaccine to prevent an infection that is afflicting more than half a billion people around the world. “This is one of the neglected tropical diseases that has the highest impact on health globally,” said David Diemert, an associate professor of microbiology, immunology and tropical medicine, who has been working with colleagues for more than a decade hoping to eradicate the effects of the hookworm parasite. Take a look at the article for more information on why you should participate in the study.
GW seeks volunteers to let parasitic worms burrow into their skin. Any takers?
Latest News
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…